重组凝血因子VIII Fc融合蛋白驱动调节性巨噬细胞极化
血友病A替代治疗的主要并发症是约30%的重型患者产生抑制物(中和性抗FVIII抗体)。本研究探讨表达Fc受体和FVIII受体的人巨噬细胞对延长半衰期重组FVIII Fc融合蛋白(rFVIIIFc)的应答,发现rFVIIIFc而非rFVIII独特地使巨噬细胞向替代激活的调节表型极化,该变化依赖rFVIIIFc-FcR相互作用。
要点
- rFVIIIFc而非rFVIII独特地使巨噬细胞向替代激活的调节表型极化。
- rFVIIIFc引发信号事件导致形态学改变及Mox/M2样调节性巨噬细胞特征性基因表达和代谢谱。
- 这些变化依赖rFVIIIFc与Fc受体的相互作用。
核心结论
- rFVIIIFc而非rFVIII独特地使巨噬细胞向替代激活的调节表型极化,该作用依赖rFVIIIFc-FcR相互作用,揭示了rFVIIIFc潜在免疫调节特性的机制。
研究设计与样本
- 体外研究,使用表达Fc受体和FVIII受体的人巨噬细胞。
主要发现
- rFVIIIFc而非rFVIII使巨噬细胞向替代激活的调节表型极化。
- rFVIIIFc引发信号事件导致形态学改变及Mox/M2样调节性巨噬细胞特征性基因表达和代谢谱。
- 上述变化依赖rFVIIIFc-FcR相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The main complication of replacement therapy with factor in hemophilia A (HemA) is the formation of inhibitors (neutralizing anti-factor VIII [FVIII] antibodies) in ∼30% of severe HemA patients. Because these inhibitors render replacement FVIII treatment essentially ineffective, preventing or eliminating them is of top priority in disease management. The extended half-life recombinant FVIII Fc fusion protein (rFVIIIFc) is an approved therapy for HemA patients. In addition, it has been reported that rFVIIIFc may induce tolerance to FVIII more readily than FVIII alone in HemA patients that have developed inhibitors. Given that the immunoglobulin G1 Fc region has the potential to interact with immune cells expressing Fc receptors (FcRs) and thereby affect the immune response to rFVIII, we investigated how human macrophages, expressing both FcRs and receptors reported to bind FVIII, respond to rFVIIIFc. We show herein that rFVIIIFc, but not rFVIII, uniquely skews macrophages toward an alternatively activated regulatory phenotype. rFVIIIFc initiates signaling events that result in morphological changes, as well as a specific gene expression and metabolic profile that is characteristic of the regulatory type Mox/M2-like macrophages. Further, these changes are dependent on rFVIIIFc-FcR interactions. Our findings elucidate mechanisms of potential immunomodulatory properties of rFVIIIFc.
引用
- Kis-Toth K, Rajani GM, Simpson A, et al. Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization. Blood Adv. 2018. PMID: 30396910. doi:10.1182/bloodadvances.2018024497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。